E. Buerger

Targeted Antioxidative and Neuroprotective Properties of the Dopamine Agonist Pramipexole and Its Nondopaminergic Enantiomer SND919CL2x [(+)2-Amino-4,5,6,7-tetrahydro-6-lpropylamino-benzathiazole Dihydrochloride]

A. Ludolph, F. Gillardon, B. Hengerer, 2006, Journal of Pharmacology and Experimental Therapeutics.

Inhibition of the Na(+)/H(+) exchanger confers greater cardioprotection against 90 minutes of myocardial ischemia than ischemic preconditioning in dogs.

G. Gross, R. Gumina, Jeannine M Moore, 1999, Circulation.

Inhibition of the Na (cid:49) /H (cid:49) Exchanger Confers Greater Cardioprotection Against 90 Minutes of Myocardial Ischemia Than Ischemic Preconditioning in Dogs

G. Gross, R. Gumina, Jeannine M Moore, 1999 .

Na(+)/H(+) exchange inhibition-induced cardioprotection in dogs: effects on neutrophils versus cardiomyocytes.

G. Gross, J. Auchampach, R. Gumina, 2000, American journal of physiology. Heart and circulatory physiology.

Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic‐pharmacodynamic study using in vivo microdialysis in rats

K. Buck, B. Ferger, P. Voehringer, 2010, Synapse.

Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model

E. Masliah, J. Winkler, B. Winner, 2009, Experimental Neurology.

Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats.

R. Oosting, B. Olivier, L. Groenink, 2009, European journal of pharmacology.

Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole

E. Buerger, S. Albrecht, 2009, Current medical research and opinion.

Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole

Maurizio Memo, Daniela Uberti, M. Memo, 2010, BMC pharmacology.